187 related articles for article (PubMed ID: 23235432)
1. Intravitreal bevacizumab in the treatment of peripapillary choroidal neovascular membrane secondary to idiopathic intracranial hypertension.
Lee IJ; Maccheron LJ; Kwan AS
J Neuroophthalmol; 2013 Jun; 33(2):155-7. PubMed ID: 23235432
[TBL] [Abstract][Full Text] [Related]
2. Management of Peripapillary Choroidal Neovascular Membrane in Patients With Idiopathic Intracranial Hypertension.
Ozgonul C; Moinuddin O; Munie M; Lee MS; Bhatti MT; Landau K; Van Stavern GP; Mackay DD; Lebas M; DeLott LB; Cornblath WT; Besirli CG
J Neuroophthalmol; 2019 Dec; 39(4):451-457. PubMed ID: 30951011
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for peripapillary subretinal neovascular membrane associated to papilledema: a case report.
Más AM; Villegas VM; García JM; Acevedo S; Serrano L
P R Health Sci J; 2012 Sep; 31(3):148-50. PubMed ID: 23038888
[TBL] [Abstract][Full Text] [Related]
4. Peripapillary choroidal neovascular membrane in a teenage boy: presenting feature of idiopathic intracranial hypertension and resolution with intravitreal bevacizumab.
Belliveau MJ; Xing L; Almeida DR; Gale JS; ten Hove MW
J Neuroophthalmol; 2013 Mar; 33(1):48-50. PubMed ID: 23403388
[TBL] [Abstract][Full Text] [Related]
5. Successful management of peripapillary choroidal neovascular membrane secondary to idiopathic intracranial hypertension with intravitreal ranibizumab.
Kumar N; Tigari B; Dogra M; Singh R
Indian J Ophthalmol; 2018 Sep; 66(9):1358-1360. PubMed ID: 30127172
[TBL] [Abstract][Full Text] [Related]
6. Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab.
Figueroa MS; Noval S; Contreras I
Br J Ophthalmol; 2008 Sep; 92(9):1244-7. PubMed ID: 18621798
[TBL] [Abstract][Full Text] [Related]
7. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
[TBL] [Abstract][Full Text] [Related]
8. Subretinal hemorrhage from a peripapillary choroidal neovascular membrane in papilledema caused by idiopathic intracranial hypertension.
Sathornsumetee B; Webb A; Hill DL; Newman NJ; Biousse V
J Neuroophthalmol; 2006 Sep; 26(3):197-9. PubMed ID: 16966941
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Ranibizumab Injection in Peripapillary CNVM Related to Idiopathic Intracranial Hypertension.
Altan-Yaycioglu R; Canan H; Saygi S
J Pediatr Ophthalmol Strabismus; 2017 Apr; 54():e27-e30. PubMed ID: 28453165
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic Peripapillary Subretinal Neovascular Membrane in a Young Woman with Recurrence of the Lesion during Pregnancy after Treatment with Intravitreal Bevacizumab.
Al-Gharbi N; Al Abdulsalam O; Al Habash A
Middle East Afr J Ophthalmol; 2015; 22(2):245-8. PubMed ID: 25949086
[TBL] [Abstract][Full Text] [Related]
11. Peripapillary neovascular membrane: a rare cause of acute vision loss in pediatric idiopathic intracranial hypertension.
Kaeser PF; Borruat FX
J AAPOS; 2011 Feb; 15(1):83-6. PubMed ID: 21397812
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri.
Jamerson SC; Arunagiri G; Ellis BD; Leys MJ
Int Ophthalmol; 2009 Jun; 29(3):183-5. PubMed ID: 18196206
[TBL] [Abstract][Full Text] [Related]
13. [Intravitreal ranibizumab injection for the treatment of idiopathic choroidal neovascularisation in young patients].
Ouhadj O; Degheb N; Idir S; Nebab A; Nouri MT
J Fr Ophtalmol; 2012 Sep; 35(7):514-22. PubMed ID: 22789650
[TBL] [Abstract][Full Text] [Related]
14. A Young Woman With Headaches and Blurry Vision.
Scott NL; Stryjewski TP; Rizzo JF
JAMA Ophthalmol; 2017 Jun; 135(6):663-664. PubMed ID: 28301650
[No Abstract] [Full Text] [Related]
15. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
19. Juxtapapillary neovascular membrane secondary to idiopathic intracranial hypertension treated with intravitreal bevacizumab: A case report.
Hernández-Ortega V; Soler-Sanchís MI; Jiménez-Escribano RM; Sanz-López AM
Arch Soc Esp Oftalmol; 2016 May; 91(5):250-4. PubMed ID: 26832628
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
